- Home
- PASG
PASG
Passage Bio Inc.
as 01-17-2025 4:00pm EST
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 42.2M | IPO Year: | 2020 |
| Target Price: | $8.00 | AVG Volume (30 days): | 886.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.45 - $1.79 | Next Earning Date: | 03-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Passage Bio Inc. (PASG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Jan 10 '25 | Sell | $0.63 | 223,219 | $142,223.38 | 7,034,626 | |
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Jan 6 '25 | Sell | $0.72 | 147,024 | $103,305.69 | 7,034,626 | |
| Lynx1 Capital Management LP | PASG | 10% Owner | Dec 27 '24 | Buy | $0.65 | 373,645 | $241,038.39 | 9,256,953 | |
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Dec 20 '24 | Sell | $0.60 | 230,321 | $138,192.60 | 7,034,626 | |
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Dec 9 '24 | Sell | $0.81 | 62,276 | $51,988.04 | 7,034,626 | |
| ORBIMED ADVISORS LLC | PASG | 10% Owner | Dec 4 '24 | Sell | $0.80 | 97,103 | $77,338.46 | 7,034,626 | |
| Lynx1 Capital Management LP | PASG | 10% Owner | Nov 25 '24 | Buy | $0.65 | 456,353 | $284,519.51 | 9,256,953 |
Latest Passage Bio Inc. News
PASG Breaking Stock News: Dive into PASG Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
Simply Wall St.
21 days ago
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
TipRanks
2 months ago
Passage Bio assumed with an Outperform at Wedbush
MT Newswires
2 months ago
Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating
MT Newswires
2 months ago
Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating
TipRanks
2 months ago
Passage Bio Achieves Milestones in Gene Therapy Trials
GlobeNewswire
2 months ago
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
2 months ago
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Compare PASG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PASG Passage Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.